BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
월요일, 9월 21

Atara Biotherapeutics Inc

ATRANASDAQ
Trade with Public
Trade with Public
$9.69
-0.02-0.21%
가까이에: Sep 17, 5:00 PM EST
$9.69
-0.02-0.21%
프리마켓: 8:01 AM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교주식 보고서

Atara Biotherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Atara Biotherapeutics (ATRA).

Price Target Range — 11 Quarters

Analyst Consensus — 8 Analysts

3Buy
4Hold
1Sell
Consensus RatingBuy# Analysts8Avg. Consensus PT$22Upside to Avg. PT+131.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
May 18, 2026Freedom BrokerIlya ZubkovUpgradeSell→Hold$4→$10
May 8, 2026Canaccord GenuityJohn NewmanUpgradeHold→Buy$6→$13
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Canaccord Genuity Upgrades Atara Biotherapeutics to Buy, Raises Price Target to $13

Canaccord Genuity analyst John Newman upgrades Atara Biotherapeutics (NASDAQ:ATRA) from Hold to Buy and raises the price target from $6 to $13.
Benzinga Newsdesk

PRO
Canaccord Genuity Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $6

Canaccord Genuity analyst John Newman downgrades Atara Biotherapeutics (NASDAQ:ATRA) from Buy to Hold and lowers the price target from $25 to $6.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $25

Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and raises the price target from $17 to $25.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $17 Price Target

Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and maintains $17 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) from Neutral to Neutral.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) from Neutral to Neutral.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved